摘要
目的通过对碳酸锂联合^(131)I治疗的Graves病患者不同时期甲状腺激素水平测定、临床症状体征的改善情况,评价治疗效果。方法将肾功能正常的68例Graves病患者分为A组(^(131)I+碳酸锂)、B组(~131)I),于^(131)I治疗0、14d和6个月回访,测定FT3、FT4和TSH值,并进行统计学分析。结果A、B两组治疗早期甲状腺激素水平、临床症状、体征及早发甲状腺功能减退发生率有明显差异,而治愈率无明显差异。结论肾功能正常时,使用碳酸锂联合^(131)I治疗Graves病,可以减少^(131)I剂量,改善治疗初期甲状腺功能,减少早发甲低的可能性。
Objective To evaluate the therapeutic effects of ^131I combined with lithium carbonate in the treatment of Graves by detecting the levels of thyroid hormones and observing the improvement of clinical symptoms and signs at different stages. Methods 68 cases of Graves patients with normal renal function were divided into group A （treated with ^131I and lithium carbonate） and group B （treated with ^131I alone）. The plasma levels of FT3, FT4 and TSH were detected during the day of treatment, 14 days and 6 months after the treatment. All data were analyzed with statistical method. Results There were significant differences in the levels of thyroid hormones, clinical symptoms, signs and the incidence of early hypothyroidism between the two groups but the curative ratio had not significant difference. Conclusion Combination of ^131I with lithium carbonate in the treatment of Graves can decrease the dose of ^131I, improve thyroid function at the early stage of treatment and reduce the possibility of early hypothyroidism.
出处
《兰州大学学报（医学版）》
CAS
2009年第2期81-83,共3页
Journal of Lanzhou University（Medical Sciences）
